- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.03. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 12.03.2025 | 550 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 12.03.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 12.03.2025ISIN NameCA3719571018 GENESIS... ► Artikel lesen | |
| 12.03. | BenevolentAI: Result of Extraordinary General Meeting and Delisting from Euronext Amsterdam | 288 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces that:
All resolutions proposed at its Extraordinary... ► Artikel lesen | |
| BENEVOLENTAI Aktie jetzt für 0€ handeln | |||||
| 12.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.03.2025 | 391 | Xetra Newsboard | Das Instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 12.03.2025 und ex Kapitalmassnahme am 13.03.2025 The instrument 4W7 CA78412Y2024 SBD CAPITAL CORP. EQUITY... ► Artikel lesen | |
| 06.02. | Proposed Delisting via Merger of BenevolentAI into Osaka Holdings S.à r.l. and Publication of Notice of Extraordinary General Meeting | 614 | Business Wire | Regulatory News:
BenevolentAI, ("BenevolentAI" or "the Company") (Euronext Amsterdam: BAI), a pioneer in AI-driven drug discovery, today announces:
Subject to shareholder approval, the proposed... ► Artikel lesen | |
| 11.12.24 | AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots | 12 | MedCity News | ||
| 11.12.24 | BenevolentAI restructures; Lilly preps $15B buyback program | 11 | BioPharma Dive | ||
| 11.12.24 | Mulvany hits the reset button at BenevolentAI | 12 | pharmaphorum | ||
| 11.12.24 | BenevolentAI pivots back to 'TechBio' roots, causing more layoffs | 11 | FierceBiotech | ||
| 11.12.24 | BenevolentAI Unveils Major Strategic Overhaul With Return to Original Mission | 330 | Business Wire | Changes mark a return to BenevolentAI's foundational strengths Initiates significant organisational restructuring Announces intention to evaluate delisting from Euronext Amsterdam
Regulatory... ► Artikel lesen | |
| 17.10.24 | BenevolentAI Appoints Kenneth Mulvany as Executive Chairman | 274 | Business Wire | Founder of leading AI drug discovery company returns to the executive management team to capitalise on the growing adoption of AI in drug discovery and development
BenevolentAI ("BenevolentAI"... ► Artikel lesen | |
| 10.10.24 | BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024 | 325 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that Dr James Malone, Chief Technology... ► Artikel lesen | |
| 19.09.24 | BenevolentAI Interim Results for the Six Months Ended 30 June 2024 | 414 | Business Wire | Strengthened Executive Leadership and Board Positive Top Line Phase I Data Reported for BEN-8744, Full Data to be Presented at Upcoming Leading Medical Conference Advancements in Target Identification... ► Artikel lesen | |
| 06.09.24 | BenevolentAI Notice of Interim Results | 397 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, will announce its interim results for the six months... ► Artikel lesen | |
| 04.07.24 | BenevolentAI: Appointment of Adviser | 395 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the... ► Artikel lesen | |
| 03.07.24 | BenevolentAI: Leadership Team Change | 460 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced artificial intelligence (AI) to accelerate biopharma drug discovery, today... ► Artikel lesen | |
| 25.06.24 | BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio | 899 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
| 19.06.24 | BenevolentAI CEO to Join Panel at Morgan Stanley 3rd Annual Life Sciences AI Summit | 389 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that it will participate in the upcoming... ► Artikel lesen | |
| 04.06.24 | BenevolentAI to participate in Goldman Sachs 45th Annual Global Healthcare Conference | 366 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that it will participate in the upcoming... ► Artikel lesen | |
| 15.05.24 | BenevolentAI Announces Further Success With AstraZeneca Collaboration as Novel Heart Failure Target Selected | 778 | Business Wire | BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target... ► Artikel lesen | |
| 02.05.24 | BenevolentAI: Result of Annual General Meeting | 333 | Business Wire | Regulatory News:
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery announces that all resolutions... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 5,775 | +0,43 % | Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? | ||
| ABCELLERA BIOLOGICS | 2,267 | -0,57 % | AbCellera Biologics Aktie: Die Falle schnappt zu? | AbCellera Biologics Inc. (ABCL) hat kürzlich Informationen zu seinen Forschungsinitiativen und finanziellen Ergebnissen veröffentlicht, die den laufenden Übergang zu einem Biotechnologieunternehmen... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 8,302 | +0,29 % | Anavex Life Sciences Aktie: Leichter Aufwärtstrend | Anavex-Aktie mit stabiler Performance und optimistischen Analystenprognosen. Biotech-Firma forciert klinische Studien für neurologische Therapien. Die Anavex Life Sciences-Aktie zeigt heute eine stabile... ► Artikel lesen | |
| VERACYTE | 28,000 | +2,19 % | Veracyte launches metastatic prostate cancer test | ||
| ASCLETIS PHARMA | 0,735 | -0,68 % | Ascletis Pharma Reports Positive Phase Ib Results For ASC30 In Treating Obesity | BEIJING (dpa-AFX) - Ascletis Pharma Inc. (ASCLF.PK) announced positive topline results from its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,810 | +0,96 % | Why Verve Therapeutics Zoomed 40% Higher This Week | ||
| BIOMEA FUSION | 2,200 | -4,35 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,175 | -0,47 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| JASPER THERAPEUTICS | 4,750 | -4,04 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria | Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single... ► Artikel lesen | |
| ABSCI | 3,170 | -1,55 % | Absci Corporation: Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results | Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci... ► Artikel lesen | |
| LANTERN PHARMA | 3,670 | 0,00 % | Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates | DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 4,035 | -1,82 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma | NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| QIAGEN | 37,020 | -1,57 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,445 | -36,08 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| EVOTEC | 7,382 | +0,52 % | Evotec: Neue Strategie und starkes Ergebnis im vierten Quartal! |
BENEVOLENTAI gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,087 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BENEVOLENTAI finden Sie auf Wallstreet Online.
